LuciRepo — Repotrectinib 40 mg, 60 pcs, Lucius

LuciRepo — Repotrectinib Capsules 40 mg, 60 Capsules

Product code: 512

30396₴ 33123₴ -8% On order · from 10 days

Analogues

LuciRepo Repotrex
1
Active ingredient
Dosage form Capsules
Capsules per pack 60

LuciRepo is an advanced targeted antineoplastic agent belonging to the kinase inhibitor class, indicated for the treatment of non-small cell lung cancer and other solid tumors harboring ROS1 or NTRK gene fusions. The active pharmaceutical ingredient is repotrectinib at a strength of 40 mg supplied as hard gelatin capsules (Repotrectinib Capsules 40 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Repotrectinib is a potent, oral, selective macrocyclic tyrosine kinase inhibitor targeting ROS1 and NTRK (TRKA, TRKB, TRKC). It is specifically engineered to overcome acquired resistance to previously administered kinase inhibitors (such as crizotinib or entrectinib) caused by point mutations within the kinase domain. The compact macrocyclic structure allows the drug to effectively bind to altered targets while ensuring superior blood-brain barrier penetration for intracranial metastasis control.

Supplied in a package containing 60 capsules of 40 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciRepo 40 mg:

  • ✅ Next-Generation ROS1/NTRK Inhibitor: High potency against wild-type and mutant kinase forms.
  • ✅ Overcoming Resistance: Efficacy in tumors resistant to prior TKI therapy.
  • ✅ High CNS Efficacy: Excellent blood-brain barrier penetration for intracranial lesion control.
  • ✅ Convenient Oral Dosing: Administered orally following a specialized initial dose titration schedule.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Augtyro).

LuciRepo is supplied as hard gelatin capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Repotrectinib — 40 mg.
  • Excipients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica. Capsule shell: gelatin, titanium dioxide, colorants.

Packaging and Presentation: Hard capsules, 40 mg strength. Each package contains 60 capsules along with prescribing information. Labeled with LuciRepo (Repotrectinib Capsules 40 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Repotrectinib is a macrocyclic tyrosine kinase inhibitor targeting ROS1, NTRK (TRKA, TRKB, TRKC), and to a lesser extent ALK. It blocks the phosphorylation of these kinases and interrupts downstream signaling cascades driving tumor cell proliferation. Due to its spatial conformation, repotrectinib maintains high activity in the presence of resistance mutations (such as ROS1 G2032R or NTRK solvent front mutations).

Pharmacokinetics:

  • Absorption: Following oral administration, repotrectinib is absorbed; peak plasma concentration (Tmax) is achieved within approximately 2 to 3 hours. High-fat meals moderately increase systemic exposure.
  • Distribution: Human plasma protein binding is high (exceeding 90%). Penetrates central nervous system tissues.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (mainly CYP3A4).
  • Elimination: Excreted predominantly via feces (approx. 85%) and renally (approx. 3%). Terminal elimination half-life (T1/2) averages approximately 11 to 13 hours.

LuciRepo is indicated in adult patients for:

  • ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
  • NTRK-Positive Solid Tumors: Treatment of adult and adolescent patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion (without acquired resistance mutations).

LuciRepo is administered orally once or twice daily depending on the treatment phase.

Dosing Regimen and Titration:
The recommended starting dose is 160 mg (four 40 mg capsules) once daily for the first 14 days. If tolerated, the dose is increased to the standard maintenance dose of 160 mg twice daily (total daily dose of 320 mg).

Administration Guidelines:
Capsules should be swallowed whole with water; do not break, crush, open, or chew. Can be taken with or without food. If a dose is missed or vomiting occurs after ingestion, take the next dose as scheduled (do not double doses).

Administration of LuciRepo is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to repotrectinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in children under 12 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.

Repotrectinib is metabolized primarily via CYP3A4:

  • Strong and Moderate CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly elevate repotrectinib plasma concentrations and toxicity risks (avoid concurrent use).
  • Strong and Moderate CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease repotrectinib blood concentrations and reduce efficacy (avoid concurrent use).
  • P-gp Substrates: The drug may affect transport proteins.

Pregnancy:
LuciRepo is contraindicated during pregnancy. Based on its mechanism of action, repotrectinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 2 months following the final dose.

Lactation:
Excretion of repotrectinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Neurological Disorders: Dizziness, ataxia, paresthesia, cognitive disorders (a frequent specific TKI class adverse effect).
  • Gastrointestinal Tract: Constipation, diarrhea, nausea, vomiting, abdominal pain.
  • General Disorders: Fatigue, peripheral edema, muscle weakness, weight increase.
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), increased blood creatine phosphokinase (CPK), anemia.
  • Cardiovascular System: Dyspnea, arterial hypotension.

Symptoms:
Specific acute overdose symptoms of repotrectinib are unestablished. Anticipated manifestations include exacerbated neurological adverse effects (dizziness, ataxia) and gastrointestinal disturbances.

Treatment:
No specific antidote exists. In case of overdose, temporarily withhold treatment and initiate supportive and symptomatic care under medical supervision.

Storage Requirements for LuciRepo 40 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciRepo 40 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Repotrectinib Capsules 40 mg, and 60 Capsules count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00